Skip to content
Home/Companies/Biotech/Artios Pharma
AP

Artios Pharma

Biotech·UK·Active·6yr hold

Artios Pharma is a healthcare company, headquartered in United Kingdom.

Entry
2020
Hold
6yr
Status
Active
Est. EV
–

Who owns Artios Pharma?

Artios Pharma is currently owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage), since 2020. Across its history, Artios Pharma has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Most recent investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC
2 ownership periods · full history below

Key facts

HQUnited Kingdom
SectorHealthcare

Ownership history

2 ownership periods · co-invest detected

Active
Co-held by Andera Partners and Sofinnova Partners since 2018.
Co-invest · 2 holders · 2018 · present
Andera Partners
Andera PartnersActive
2018 · present · BioDiscovery 5 · 2017 · VC
MOIC
–
Sofinnova Partners
Sofinnova PartnersActive
2020 · present · Sofinnova Crossover Fund I · 2018 · VC
MOIC
–

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
Active
BiotechFrance
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUnited Kingdom· 2021
to
Calliditas
Exited 2024
BiotechSweden· 2020
to
Hemab Therapeutics
Active
BiotechDenmark· 2020
F2G
Active
BiotechUK· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings